35 results about "Dopamine transporter" patented technology

The invention provides a conjugate comprising (i) a selectivity agent which binds specifically to one or more neurotransmitter transporters selected from the group consisting of a dopamine transporter (DAT), serotonin transporter (SERT) or a norepinephrine transporter (NET) and (ii) a nucleic acid capable of specifically binding to a target molecule which is expressed in the same cell as the neurotransmitter transporter wherein said target molecule is α-synuclein or the mRNA encoding α-synuclein. The conjugates of the present invention are useful for the delivery of the nucleic acid to a cell of interest and thus, for the treatment of diseases which require a down-regulation of the protein encoded by the target nucleic acid as well as for the delivery of imaging agents to the cells for diagnostic purposes.

The present invention relates to a method of detecting a therapeutic cell expressing a dopamine transporter (DAT) at a central nervous system (CNS) site in a subject, which comprises the administration of a DAT tracer to the subject, wherein the presence of a therapeutic cell which expresses the DAT is determined.

The invention relates to a radioactive compound labeling technology in the field of positron imaging agents, in particular to a method for synthesizing carbon-11 labeled N-methyldopamine hydrochloride. The preparation method comprises the following steps of: A, fully reacting 200 to 300mCi of carbon-11 methyl iodide (II) with 3 to 6mg of dopamine hydrochloride (III) dissolved and neutralized by excessive 0.1mol/L sodium bicarbonate solution at the temperature of between 70-85DEG C, and cooling to room temperature to obtain reaction liquid; and B, blowing the reaction liquid in the step A to dryness, separating, collecting a substance with a radioactive component, wherein the radioactive component is the carbon-11 labeled N-methyldopamine hydrochloride (I). The carbon-11 labeled N-methyldopamine hydrochloride has strong affinity with a dopamine transporter and a norepinephrine transporter, can early discover the change of cardiac sympathetic nerves, and provides a strong evidence for early diagnosis and treatment of heart disease; and the preparation method is simple and practicable, good in repeatability, low in synthetic cost and stable in yield.

Disclosed herein are a method and a kit using a novel marker associated with depression. The marker for depression includes one or more selected from a noradrenaline transporter and a dopamine transporter. The method for determining depression includes a step of examining an expression level of the marker for depression in a blood sample collected from a subject.

The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease, disorder or condition ameliorated by inhibition of a dopamine transporter); and methods of treating patients with such compounds; wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁹, R¹⁰, Q, X, Y, Z, A, L, B, m, n and p are as defined herein.

A semi-automatic quantification method based on a development specificity extraction ratio of a dopamine transporter includes the following steps of collecting faulted image data of the dopamine transporter; calibrating a faulted image range where a corpus striatum is located in the collected faulted image data; automatically dividing a corpus striatum area and a reference area in each calibrated faulted image; extracting the grey values of all pixels in the corpus striatum areas to serve as corpus striatum area specificity extraction count values; extracting the grey values of all pixels in the reference areas to serve as reference area specificity extraction count values; summarizing the corpus striatum area specificity extraction count values and the reference area specificity extraction count values in all the calibrated faulted images, and working out the ratio to serve as the development specificity extraction ratio. The semi-automatic quantification method can improve the efficiency, accuracy and robustness of development analysis of the dopamine transporter.

The invention relates to a non-therapeutic application of miR-212 to regulation of DAT (dopamine transporter) gene expression in cells, and further relates to a non-therapeutic method for regulating the DAT gene expression in the cells. The method comprises the step of increasing or reducing the amount of miR-212 in the cells. The invention further relates to an application of miR-212, a miR-212 enhancer or a miR-212 attenuator to preparation of a drug for regulating dopamine uptake of the cells, and further relates to an application of miR-212, the miR-212 enhancer or the miR-212 attenuator to preparation of a drug for treating psychoactive substance addiction.

A diagnostic formulation is provided comprising a tropane having a radioactive concentration of at least 1.6 mCi/mL at least about 51 hours post creation. The diagnostic formulation optionally comprises a radiolabeled dopamine transporter (DAT) ligand useful in the diagnosis of Parkinson's disease (PS). One example of a radiolabeled dopamine transporter (DAT) ligand example is [¹²³I]-N-(3-iodoprop-2E-enyl)-2β-carbomethoxy-3β-(4-methylphenyl) nortropane.

The invention discloses a 3-cyanophenoxyalkyl aryl piperazine derivative and applications in the preparation of drugs. The 3-cyanophenoxyalkyl aryl piperazine derivative shows the effect on central nervous systems, especially on 5-HT<1A> receptor selective high affinity interaction, but has no obvious affinity interaction on dopamine D1 and D2 receptors, adrenergic receptor alpha 1 and alpha 2, SERT (5-HT transporter protein), NET (adrenergic transporter protein), DAT (dopamine transporter protein) and other central related receptors and proteins. Various physiological and pharmacological effects are brought into play in the body; and the compound can be used as a pharmaceutical active substance, especially used for diseases like anti-depression, anti-anxiety and anti-neuropathic pain, andcan also be used as an intermediate to prepare other pharmaceutical active compounds. The compound is fast in effect and small in toxic and side effect, and can meet demands of clinical applications;and the compound is a compound having the following structural formula or a free base or salt thereof. The structure of the compound is shown in the description.

Disclosed is a composition and method for a therapeutic treatment that is able to combat neuroinflammation caused by diseases and disorders such as Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The class of urea compounds acts by blocking at targeted receptors in the brain that contribute to the increase in inflammation. Combinations of receptors, H1 receptor, H2 receptor, dopamine transporter (DAT), and/or 5HT3C receptor, are individually and/or collectively inhibited by the same compositions of the present disclosure, and this ability leads to a decrease in brain edema. The DAT inhibitory effects additionally maintains dopamine levels in a patient.

Cortex dictamni is an important traditional Chinese medicinal material. The invention introduces a novel function of active ingredients of cortex dictamni. The action experiment of the active ingredients of cortex dictamni for primary neuron of rats discovers that overexpression of a dopamine transporter gene DAT can be promoted by adding the active ingredients of cortex dictamni, dopaminergic neuron has an important influence on motion, addiction, motion control and other behaviors, and results indicate that changes of human body pleasant sensation, motion control and other functions can be promoted by means of application of the active ingredients of cortex dictamni.

The invention relates to a full-automatic dopamine transporter semi-quantitative value detection method based on image processing. The method comprises the following steps: (1) constructing an MRI image segmentation network, and segmenting a caudal nucleus region, a shell nucleus region and a pale globe region in a brain MRI image; (2) registering the MRI image to a PET image to obtain a segmentation result of the PET image; (3) performing clustering fine segmentation on the segmentation result of the PET image to obtain a plurality of label structures; (4) acquiring the characteristic statistics of each label structure; (5) correspondingly acquiring characteristic statistics of a top pillow leaf area in the PET image, and standardizing the characteristic statistics in each label structureby taking the characteristic statistics of the top pillow leaf area as a reference to obtain a semi-quantitative value of each characteristic statistics; and (6) performing T test on the semi-quantitative value of each label structure to finish saliency sorting of the semi-quantitative values. Compared with the prior art, the method is high in detection precision, convenient to implement and flexible in application.

The invention provides an operation method of a brain dopamine transporter examination system. The operation method comprises the following steps of: 1, detecting a brain dopamine transporter; acquiring a scanning image of the brain of the testee from the scanner, wherein the scanning image is a three-dimensional image; aligning the scanning image to a standard brain space to obtain a normalized scanning image; performing image intensity standardization on the normalized scanning image; converting the normalized scanning image after the image intensity standardization into a two-dimensional image; cutting out a plurality of image data for at least one region of interest of the two-dimensional image, wherein the region of interest comprises a left side tail core, a left side shell core, a right side tail core and a right side shell core; based on a plurality of image data, a dopaminergic neuron loss degree measurement evaluation model is established by transfer learning, so that the images are classified in the most probable neuron loss stage, an additional auxiliary diagnosis mode is provided for nuclear medical doctors to interpret brain dopamine transporter examination every time, and the accuracy of brain dopamine transporter examination is improved. And the diagnosis rate and the treatment result of clinicians are improved.